Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin+S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer
作者机构：Department of Gastrointestinal OncologyThe Affiliated Hospital of Qinghai UniversityXining 810000Qinghai ProvinceChina Department of Interventional MedicineXi’an No.3 HospitalThe Affiliated Hospital of Northwestern UniversityXi’an 710018Shaanxi ProvinceChina Department of RadiologyLuoyang No.6 People's HospitalLuoyang 471000Henan ProvinceChina Department of Gastrointestinal SurgeryThe Affiliated Hospital of Qinghai UniversityXining 810000Qinghai ProvinceChina
出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文）)
年 卷 期：2024年第16卷第10期
页 面：3224-3238页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by The Department of Science and Technology of Qinghai Province,No.2018-SF-113 "Kunlun Talents-Plateau Famous Doctors"Project in Qinghai Province
主 题：Nab-paclitaxel Gastric cancer Efficacy Safety
摘 要：BACKGROUND Gastric cancer(GC)is a relatively frequent clinical phenomenon,referring to ma-lignant tumors emerging in the gastric mucosal epithelial *** has a high mor-bidity and mortality rate,posing a significant threat to the health of ***,how to diagnose and treat GC has become a heated topic in this research *** To discuss the effectiveness and safety of nab-paclitaxel in combination with oxaliplatin and S-1(P-SOX)for the treatment of GC,and to analyze the factors that may influence its *** A total of 219 eligible patients with advanced GC,who were treated at Qinghai University Affiliated Hospital Gastrointestinal Oncology between January 2018 and March 2020,were included in the *** them,149 patients received SOX regimen and 70 patients received S-1 *** patients underwent both preoperative and postoperative chemotherapy consisting of 2-4 cycles each,totaling 6-8 cycles,along with parallel D2 radical surgical *** patients were followed up for a period of three years or until reaching the event *** The short-term and long-term efficacy of the P-SOX group was significantly higher than that of the SOX group,and the safety was *** multivariate analysis revealed that progression-free survival was associated with perioperative chemotherapy efficacy,tumor diameter≤2cm,high differentiation,and early cTNM(T stands for invasion depth;N stands for node metastasis;M stands for distant invasion)*** In comparison to the SOX regimen,the P-SOX regimen demonstrates improved short-term and long-term efficacy with tolerable adverse *** is anticipated that the P-SOX regimen will emerge as a first-line chemotherapy option for *** with GC who receive effective perioperative chemotherapy(Response Evaluation Criteria in Solid Tumors 1.1,Tumor Regression Grade),have a tumor diameter≤2cm,exhibit high degree of differentiation,and are at an early cTNM stage show better prognos
维普期刊数据库